Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats.

ABSTRACT:

Background

Drugs that act on the central nervous system (CNS) and have sedative effects can lead to abuse in humans. New CNS-active drugs often require evaluation of their abuse potential in dedicated animal models before marketing approval. Daridorexant is a new dual orexin receptor antagonist (DORA) with sleep-promoting properties in animals and humans. It was approved in 2022 in the United States and Europe for the treatment of insomnia disorder.

Aims

Nonclinical evaluation of abuse potential of daridorexant using three specific rat models assessing reinforcement, interoception, and withdrawal.

Methods

Reinforcing effects of daridorexant were assessed in an operant rat model of intravenous drug self-administration. Similarity of interoceptive effects to those of th

SUBMITTER: Steiner MA 

PROVIDER: S-EPMC10714714 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature